| oditrasertib (DNL788) / Denali Therap, Sanofi |
NCT05795907: Single & Multiple Ascending Dose Study of SAR443820 in Healthy Adult Participants |
|
|
| Completed | 1 | 84 | US | SAR443820, Placebo | Sanofi | Amyotrophic Lateral Sclerosis (Healthy Volunteers) | 07/21 | 07/21 | | |
NCT05797701: A Study in Healthy Adult Male & Female Participants to Assess the Amount of the Study Medicine (SAR443820) Absorbed by the Body, When Given Orally in Fasted Condition as a Tablet Versus as a Capsule (Part 1) and When Given Orally as a Tablet in Fasted Condition Versus as a Tablet After Food (Part 2) |
|
|
| Completed | 1 | 18 | US | SAR443820 | Sanofi | Amyotrophic Lateral Sclerosis (Healthy Volunteers) | 09/21 | 09/21 | | |
NCT04982991: Single Ascending Dose Study of SAR443820 in Healthy Adult Chinese and Japanese Female and Male Participants |
|
|
| Completed | 1 | 14 | Europe | RIPK1 inhibitor, SAR443820 | Sanofi | Multiple Sclerosis Healthy Subjects | 10/21 | 10/21 | | |
NCT05797753: A Study to Assess the Effect of Erythromycin on the Test Medicine (SAR443820) When Given Orally as Tablets to Healthy Adult Male and Female Participants (Part A); and the Effect of Itraconazole on the Test Medicine (SAR443820) When Given Orally as Capsules to Healthy Adult Male Participants (Part B) |
|
|
| Completed | 1 | 16 | US | SAR443820, Erythromycin ethyl succinate, Itraconazole | Sanofi | Amyotrophic Lateral Sclerosis (Healthy Volunteers) | 07/22 | 07/22 | | |
